27 September 2022

Incanthera plc

("Incanthera" or the "Company")

Issue of Equity

Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in dermatology and oncology announces that it has issued 2,302,157 ordinary shares in the Company ("New Ordinary Shares") at a price of 6.95 pence per share to service providers in lieu of contractual amounts owed.

Furthermore, the Company has issued 1,079,136 warrants over ordinary shares, with an exercise price of 6.95 pence per share and an exercise period of five years from the date of issue.

It is expected that admission of the shares will become effective at 8.00 a.m. on or around 3 October 2022.

Following admission of the New Ordinary Shares, the Company's enlarged issued share capital will comprise 76,385,028 ordinary shares of 2 pence each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in the interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018).

The directors of the Company take responsibility for this announcement.

For further enquiries:

Incanthera plc:                                                                                                                                                                       

Notes to Editors

Incanthera is dedicated to innovative technologies in dermatology and oncology.  It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.

Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com

@incantheraplc